Clinical Trial Update: Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for CD19-directed CAR-T cell therapy in patients with refractory or relapsed B lymphoid malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• CD19-directed CAR-T cell therapy

Snippet

Sponsor: Nelson Hamerschlak | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory | Phase 1 | Status: RECRUITING